Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of ALLN-177 Treatment Over 28 Days in Patients With Secondary Hyperoxaluria and Kidney Stones

NCT02547805 is registered in ClinicalTrials.gov with Allena Pharmaceuticals as lead sponsor.

NCT NCT02547805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02547805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of ALLN-177 Treatment Over 28 Days in Patients With Secondary Hyperoxaluria and Kidney Stones
Lead sponsor
Allena Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2015
Completion date
January 31, 2017
Enrollment
66 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

dietary hyperoxaluria, hyperoxaluria, kidney stones, nephrolithiasis, secondary hyperoxaluria